Annelisa M. Cornel

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models.

CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models.

Journal: The Journal of clinical investigation
Published: November 25, 2025

Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas.

Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas.

Journal: Molecular therapy. Oncology
Published: June 23, 2025

De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function.

De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function.

Journal: Nature cancer
Published: May 07, 2025

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL.

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL.

Journal: Blood neoplasia
Published: May 06, 2024

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia.

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia.

Journal: Haematologica
Published: April 18, 2024

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.

Journal: Journal for immunotherapy of cancer
Published: March 18, 2024

Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.

Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.

Journal: Journal for immunotherapy of cancer
Published: December 18, 2023

Thymic NK-Cells and Their Potential in Cancer Immunotherapy.

Thymic NK-Cells and Their Potential in Cancer Immunotherapy.

Journal: ImmunoTargets and therapy
Published: September 22, 2023

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.

Journal: Journal for immunotherapy of cancer
Published: June 28, 2023

BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response.

BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response.

Journal: Nature protocols
Published: June 13, 2023

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.

Journal: Cancer cell
Published: February 15, 2023

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.

Journal: Journal for immunotherapy of cancer
Published: September 22, 2022
Showing 1-12 of 23

Last Updated: 09/26/2026